Maravai LifeSciences (NASDAQ:MRVI) Hits New 1-Year Low – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $4.24 and last traded at $4.31, with a volume of 2124132 shares trading hands. The stock had previously closed at $4.58.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Robert W. Baird dropped their price target on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Royal Bank of Canada decreased their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Wolfe Research started coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Guggenheim started coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Stock Performance

The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock has a market cap of $1.08 billion, a PE ratio of -2.60 and a beta of -0.08. The business’s 50-day moving average price is $5.28 and its 200-day moving average price is $6.93.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.63% of the stock is owned by insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of MRVI. Massachusetts Financial Services Co. MA increased its stake in Maravai LifeSciences by 29.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company’s stock valued at $25,420,000 after purchasing an additional 1,062,485 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Maravai LifeSciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,794,961 shares of the company’s stock valued at $15,236,000 after acquiring an additional 42,884 shares during the period. JPMorgan Chase & Co. increased its position in shares of Maravai LifeSciences by 4.9% in the 4th quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company’s stock valued at $23,166,000 after acquiring an additional 200,411 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Maravai LifeSciences by 118.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 52,508 shares of the company’s stock worth $298,000 after acquiring an additional 28,480 shares during the last quarter. Finally, Pier Capital LLC grew its stake in Maravai LifeSciences by 137.0% during the 4th quarter. Pier Capital LLC now owns 1,127,773 shares of the company’s stock valued at $6,146,000 after purchasing an additional 651,921 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.